Rigel said Vepenew, acquired in June and launched in mid-August, generated 6.6 million in sales in its first six weeks. Net product sales of 72 million in the past quarter were the company's largest quarterly figure ever. The company plans to present updated R289 data at the ASH meeting in December and start a registrational study in 2027 with FDA concurrence.
RIGL · Rigel Pharmaceuticals Inc · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Rigel generated $72.3 million in net product sales for the third quarter of 2026, up 13% year-over-year, including $6.6 million from Vepenu.
Rigel reported third-quarter total revenues of $80.9 million and net income of $13.2 million, while VEPPANU generated $6.6 million in initial net product sales. It updated the 2026 revenue outlook to approximately $290 to $295 million, excluding VEPPANU.
VEPPANU generated $6.6 million in initial net product sales from its August 13, 2026 launch through September 30, 2026, while nine-month TAVALISSE sales rose 15% to $130.6 million.